Cargando…
Surfactant therapies for pediatric and neonatal ARDS: ESPNIC expert consensus opinion for future research steps
Pediatric (PARDS) and neonatal (NARDS) acute respiratory distress syndrome have different age-specific characteristics and definitions. Trials on surfactant for ARDS in children and neonates have been performed well before the PARDS and NARDS definitions and yielded conflicting results. This is main...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7898495/ https://www.ncbi.nlm.nih.gov/pubmed/33618742 http://dx.doi.org/10.1186/s13054-021-03489-6 |
_version_ | 1783653871585853440 |
---|---|
author | De Luca, Daniele Cogo, Paola Kneyber, Martin C. Biban, Paolo Semple, Malcolm Grace Perez-Gil, Jesus Conti, Giorgio Tissieres, Pierre Rimensberger, Peter C. |
author_facet | De Luca, Daniele Cogo, Paola Kneyber, Martin C. Biban, Paolo Semple, Malcolm Grace Perez-Gil, Jesus Conti, Giorgio Tissieres, Pierre Rimensberger, Peter C. |
author_sort | De Luca, Daniele |
collection | PubMed |
description | Pediatric (PARDS) and neonatal (NARDS) acute respiratory distress syndrome have different age-specific characteristics and definitions. Trials on surfactant for ARDS in children and neonates have been performed well before the PARDS and NARDS definitions and yielded conflicting results. This is mainly due to heterogeneity in study design reflecting historic lack of pathobiology knowledge. We reviewed the available clinical and preclinical data to create an expert consensus aiming to inform future research steps and advance the knowledge in this area. Eight trials investigated the use of surfactant for ARDS in children and ten in neonates, respectively. There were improvements in oxygenation (7/8 trials in children, 7/10 in neonates) and mortality (3/8 trials in children, 1/10 in neonates) improved. Trials were heterogeneous for patients’ characteristics, surfactant type and administration strategy. Key pathobiological concepts were missed in study design. Consensus with strong agreement was reached on four statements: 1. There are sufficient preclinical and clinical data to support targeted research on surfactant therapies for PARDS and NARDS. Studies should be performed according to the currently available definitions and considering recent pathobiology knowledge. 2. PARDS and NARDS should be considered as syndromes and should be pre-clinically studied according to key characteristics, such as direct or indirect (primary or secondary) nature, clinical severity, infectious or non-infectious origin or patients’ age. 3. Explanatory should be preferred over pragmatic design for future trials on PARDS and NARDS. 4. Different clinical outcomes need to be chosen for PARDS and NARDS, according to the trial phase and design, trigger type, severity class and/or surfactant treatment policy. We advocate for further well-designed preclinical and clinical studies to investigate the use of surfactant for PARDS and NARDS following these principles. [Image: see text] |
format | Online Article Text |
id | pubmed-7898495 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-78984952021-02-23 Surfactant therapies for pediatric and neonatal ARDS: ESPNIC expert consensus opinion for future research steps De Luca, Daniele Cogo, Paola Kneyber, Martin C. Biban, Paolo Semple, Malcolm Grace Perez-Gil, Jesus Conti, Giorgio Tissieres, Pierre Rimensberger, Peter C. Crit Care Review Pediatric (PARDS) and neonatal (NARDS) acute respiratory distress syndrome have different age-specific characteristics and definitions. Trials on surfactant for ARDS in children and neonates have been performed well before the PARDS and NARDS definitions and yielded conflicting results. This is mainly due to heterogeneity in study design reflecting historic lack of pathobiology knowledge. We reviewed the available clinical and preclinical data to create an expert consensus aiming to inform future research steps and advance the knowledge in this area. Eight trials investigated the use of surfactant for ARDS in children and ten in neonates, respectively. There were improvements in oxygenation (7/8 trials in children, 7/10 in neonates) and mortality (3/8 trials in children, 1/10 in neonates) improved. Trials were heterogeneous for patients’ characteristics, surfactant type and administration strategy. Key pathobiological concepts were missed in study design. Consensus with strong agreement was reached on four statements: 1. There are sufficient preclinical and clinical data to support targeted research on surfactant therapies for PARDS and NARDS. Studies should be performed according to the currently available definitions and considering recent pathobiology knowledge. 2. PARDS and NARDS should be considered as syndromes and should be pre-clinically studied according to key characteristics, such as direct or indirect (primary or secondary) nature, clinical severity, infectious or non-infectious origin or patients’ age. 3. Explanatory should be preferred over pragmatic design for future trials on PARDS and NARDS. 4. Different clinical outcomes need to be chosen for PARDS and NARDS, according to the trial phase and design, trigger type, severity class and/or surfactant treatment policy. We advocate for further well-designed preclinical and clinical studies to investigate the use of surfactant for PARDS and NARDS following these principles. [Image: see text] BioMed Central 2021-02-22 /pmc/articles/PMC7898495/ /pubmed/33618742 http://dx.doi.org/10.1186/s13054-021-03489-6 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review De Luca, Daniele Cogo, Paola Kneyber, Martin C. Biban, Paolo Semple, Malcolm Grace Perez-Gil, Jesus Conti, Giorgio Tissieres, Pierre Rimensberger, Peter C. Surfactant therapies for pediatric and neonatal ARDS: ESPNIC expert consensus opinion for future research steps |
title | Surfactant therapies for pediatric and neonatal ARDS: ESPNIC expert consensus opinion for future research steps |
title_full | Surfactant therapies for pediatric and neonatal ARDS: ESPNIC expert consensus opinion for future research steps |
title_fullStr | Surfactant therapies for pediatric and neonatal ARDS: ESPNIC expert consensus opinion for future research steps |
title_full_unstemmed | Surfactant therapies for pediatric and neonatal ARDS: ESPNIC expert consensus opinion for future research steps |
title_short | Surfactant therapies for pediatric and neonatal ARDS: ESPNIC expert consensus opinion for future research steps |
title_sort | surfactant therapies for pediatric and neonatal ards: espnic expert consensus opinion for future research steps |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7898495/ https://www.ncbi.nlm.nih.gov/pubmed/33618742 http://dx.doi.org/10.1186/s13054-021-03489-6 |
work_keys_str_mv | AT delucadaniele surfactanttherapiesforpediatricandneonatalardsespnicexpertconsensusopinionforfutureresearchsteps AT cogopaola surfactanttherapiesforpediatricandneonatalardsespnicexpertconsensusopinionforfutureresearchsteps AT kneybermartinc surfactanttherapiesforpediatricandneonatalardsespnicexpertconsensusopinionforfutureresearchsteps AT bibanpaolo surfactanttherapiesforpediatricandneonatalardsespnicexpertconsensusopinionforfutureresearchsteps AT semplemalcolmgrace surfactanttherapiesforpediatricandneonatalardsespnicexpertconsensusopinionforfutureresearchsteps AT perezgiljesus surfactanttherapiesforpediatricandneonatalardsespnicexpertconsensusopinionforfutureresearchsteps AT contigiorgio surfactanttherapiesforpediatricandneonatalardsespnicexpertconsensusopinionforfutureresearchsteps AT tissierespierre surfactanttherapiesforpediatricandneonatalardsespnicexpertconsensusopinionforfutureresearchsteps AT rimensbergerpeterc surfactanttherapiesforpediatricandneonatalardsespnicexpertconsensusopinionforfutureresearchsteps |